March 15, 2017
The KI’s Irvine and Wittrup Labs’ work in immunotherapy is a slam-dunk contender for STAT Madness! Selected to represent MIT in STAT's NCAA-style bracket among 32 leading research organizations, this powerful new combination immunotherapy acts at each key juncture of the immune cycle to promote a sustained response and activates both arms of the immune system. The vaccine’s targeting is modular and can be adapted to various cancer types. The project represents the best of what we do at the KI and MIT: combining deep scientific understanding with novel engineering approaches to improve access to life-changing technologies. Second round voting ends at the end of the day on Thursday, March 16, so vote now to advance KI research to the next round by filling out your bracket here.